Development and Validation of a Time‐Dependent Nomogram for Predicting Hematological Toxicity Risk During Linezolid Therapy in Drug‐Resistant Tuberculosis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026
DOI: 10.1002/phar.70109 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2026. Verfasst von Wenqiang Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Nomograms, Linezolid, Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Ministry of Science and Technology.
Abstract (Originalsprache)
Background
Linezolid is essential for drug‐resistant tuberculosis (DR‐TB) treatment but causes frequent hematological toxicity. We developed a time‐dependent nomogram to predict this risk.
Methods
A prospective cohort of 201 patients with DR‐TB receiving linezolid (600 mg/day) was enrolled. Blood trough concentration (C min ) and clinical variables were measured. Multivariable Cox regression identified predictors, with a nomogram constructed to estimate toxicity probability at 1, 3, and 6 months. Model performance was assessed via calibration curves, C‐index, and time‐dependent area under the curve (AUC).
Results
Ninety‐six patients (47.8%) developed hematological adverse events (anemia: 26.4%, leukopenia: 14.4%, thrombocytopenia: 7.0%). Five predictors were significant: C min > 2.08 mg/L [Hazard Ratio (HR) = 2.87, p < 0.001]; lower baseline white blood cells (HR = 0.84, p = 0.003), hemoglobin (HR = 0.99, p = 0.033), and creatinine clearance rate (HR = 0.99, p = 0.001); and initial treatment (HR = 0.56 vs. retreatment, p = 0.011). The nomogram showed good discrimination (C‐index = 0.73) and calibration. Time‐dependent AUCs were 0.74 (1‐month), 0.79 (3‐month), and 0.80 (6‐month). Internal validation via bootstrapping (1000×) confirmed robustness.
Conclusions
This nomogram, integrating C min with baseline clinical factors, enables early identification of patients with DR‐TB at high risk for hematotoxicity and could guide pre‐emptive interventions. However, external validation is required to confirm its generalizability before widespread clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Tuberculosis Department, Beijing Chest Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Wenqiang Zhou, Wenjie Qi, Yu Lu, Naihui Chu
Förderung
- Ministry of Science and Technology
Zitieren
APA
Zhou, W., Zhu, H., Liu, Z., Nie, W., Wang, Q., Shi, W., Yang, Y., Qi, W., Lu, Y., & Chu, N. (2026). Development and Validation of a Time‐Dependent Nomogram for Predicting Hematological Toxicity Risk During Linezolid Therapy in Drug‐Resistant Tuberculosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70109
Vancouver
Zhou W, Zhu H, Liu Z, Nie W, Wang Q, Shi W, et al. Development and Validation of a Time‐Dependent Nomogram for Predicting Hematological Toxicity Risk During Linezolid Therapy in Drug‐Resistant Tuberculosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026. doi:10.1002/phar.70109
BibTeX
@article{Zhou2026,
author = {Zhou, Wenqiang and Zhu, Hui and Liu, Zhongquan and Nie, Wenjuan and Wang, Qingfeng and Shi, Wenhui and Yang, Yang and Qi, Wenjie and Lu, Yu and Chu, Naihui},
title = {Development and Validation of a Time‐Dependent Nomogram for Predicting Hematological Toxicity Risk During Linezolid Therapy in Drug‐Resistant Tuberculosis},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
doi = {10.1002/phar.70109}
}
EUVIMED